It is not unusual to read about another drug failure in a challenging neurological disease such as multiple sclerosis, Alzheimer’s disease, or Parkinson’s disease. Designing therapeutics with exquisite specificity has been the goal of modern drug development, and significant resources continue to be allocated towards this approach, only to see treatments fail due to inadequate … Continue reading “Hitting the Target, Missing the Mark: How Targeted Therapies Have Left Patients Wanting”
Author: Richard Watson
Richard Watson is the director of clinical research at Tacoma, WA-based Revalesio.